Dr. Younes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
430 E 29th St,
New York, NY 10016Phone+1 301-398-0000
Summary
Education & Training
- Memorial Sloan-Kettering Cancer CenterFellow, medical oncology, 1989 - 1992
- SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1986 - 1989
- University of ToledoResidency, Pathology-Anatomic and Clinical, 1985 - 1986
- Damascus University Faculty of MedicineClass of 1983
Certifications & Licensure
- NY State Medical License 1988 - 2027
- NJ State Medical License 2019 - 2021
- TX State Medical License 1992 - 2013
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- top doctor castle connoly, 2017
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease Start of enrollment: 1998 Feb 01
- Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2000 Sep 01
- A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma Start of enrollment: 2001 May 18
- Join now to see all
Publications & Presentations
PubMed
- 241 citationsMajor Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin LymphomaMargaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine Pak, Sara Abdelrahman
Journal of Clinical Oncology. 2018-02-02 - 1169 citationsStandards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Patholo...Marilyn M. Li, Michael B. Datto, Eric J. Duncavage, Shashikant Kulkarni, Neal I. Lindeman
The Journal of Molecular Diagnostics. 2017-01-01 - 25 citationsThe Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: A phase I, open-label, single dose-escalation studyJulie M. Vose, Jonathan W. Friedberg, Edmund K. Waller, Bruce D. Cheson, Vasthala Juvvigunta
Leukemia & Lymphoma. 2013-04-01
Journal Articles
- Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin LymphomaPeter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
- NOXA Genetic Amplification or Pharmacologic Induction Primes Lymphoma Cells to BCL2 Inhibitor-Induced Cell DeathAnas Younes, MD, Proceedings of the National Academy of Sciences
- Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II StudyFrancesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica
Abstracts/Posters
- Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 StudyAnas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix TrialAnas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Taking on New Challenges: 8 Questions with Gilles SallesDecember 23rd, 2020
- Physicians’ Education Resource® Presents the 3rd Annual Live Medical Crossfire®: Hematologic MalignanciesJune 20th, 2019
- Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesOctober 4th, 2018
- Join now to see all
Committees
- Co-author, Committee on Appropriateness Criteria, Expert Panel on Radiation Oncology - Lymphoma, American College of Radiology 2015 - Present
External Links
- Anas Younes, M.D.https://www.facebook.com/Anas-Younes-MD-119508836687/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: